Published in Dig Dis Sci on January 01, 2000
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis (2004) 1.63
Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother (2001) 1.60
Quadruplex real-time PCR assay using allele-specific scorpion primers for detection of mutations conferring clarithromycin resistance to Helicobacter pylori. J Clin Microbiol (2008) 1.14
DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob Agents Chemother (2001) 1.11
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol (2017) 1.11
Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract (2012) 1.10
Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother (2002) 1.04
Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol (2006) 1.02
Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol (2011) 1.00
Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother (2005) 0.99
"Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol (2008) 0.99
A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol (2007) 0.98
Clarithromycin resistance and eradication of Helicobacter pylori in children. Antimicrob Agents Chemother (2001) 0.96
Molecular testing for antibiotic resistance in Helicobacter pylori. Gut (2002) 0.92
Causes of failure of eradication of Helicobacter pylori. BMJ (2002) 0.91
Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol (2009) 0.89
Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol (2010) 0.88
Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep (2009) 0.88
A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine. World J Gastroenterol (2009) 0.88
Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol (2014) 0.86
First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol (2010) 0.84
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci (2008) 0.83
Prevalence of Helicobacter pylori infection and the incidence of ureA and clarithromycin resistance gene 23S rRNA genotypes status in Saudi Arabia. Saudi J Biol Sci (2012) 0.82
Differentiation of metronidazole-sensitive and -resistant clinical isolates of Helicobacter pylori by immunoblotting with antisera to the RdxA protein. J Clin Microbiol (2001) 0.82
Helicobacter pylori eradication therapy: A review of current trends. Niger Med J (2013) 0.82
In vitro activity of clarithromycin against intracellular Helicobacter pylori. Antimicrob Agents Chemother (2001) 0.80
Breath and string test: a diagnostic package for the identification of treatment failure and antibiotic resistance of Helicobacter pylori without the necessity of upper gastrointestinal endoscopy. World J Gastroenterol (2005) 0.80
Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. J Korean Med Sci (2014) 0.78
Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails. Therap Adv Gastroenterol (2009) 0.78
Centralized isolation of Helicobacter pylori from multiple centers and transport condition influences. World J Gastroenterol (2015) 0.77
Clinical trial report: Eradication of Helicobacter pylori reduces the risk for subsequent gastric cancer. Curr Gastroenterol Rep (2010) 0.75
Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study. Curr Ther Res Clin Exp (2004) 0.75
Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet (1995) 5.14
Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet (1994) 4.07
A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med (1988) 3.91
Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology (1992) 3.02
Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology (1998) 2.79
Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol (1988) 2.52
Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett (1996) 2.42
Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther (1997) 2.01
Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother (1992) 1.92
Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol (1990) 1.83
In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother (1990) 1.83
Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol (1996) 1.80
Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut (1994) 1.75
Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med (1993) 1.74
Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis (1992) 1.65
Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther (1995) 1.61
Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis (1994) 1.42
Gastroenterologists in Sydney--histology and helicobacter. Lancet (1990) 1.41
Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter (1999) 1.33
One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther (1997) 1.16
Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients. Scand J Gastroenterol (1992) 1.16
Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut (1990) 1.15
Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol (1993) 1.08
Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother (1994) 1.06
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study. Eur J Gastroenterol Hepatol (1995) 1.04
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. Leber Magen Darm (1995) 1.00
Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut (1996) 0.93
Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol (1997) 0.93
Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther (1995) 0.88
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol Ther (1997) 0.87
Effectiveness of a five times daily triple therapy regimen against Helicobacter pylori. J Antimicrob Chemother (1994) 0.79
An audit of low dose triple therapy for eradication of Helicobacter pylori. N Z Med J (1996) 0.75
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 9.77
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother (1996) 6.01
Norwalk virus genome cloning and characterization. Science (1990) 5.83
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet (1987) 5.02
Proteolytic enhancement of rotavirus infectivity: molecular mechanisms. J Virol (1981) 4.87
In vitro transcription and translation of simian rotavirus SA11 gene products. J Virol (1980) 4.40
Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med (1993) 4.36
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol (1999) 4.13
Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology (1998) 4.12
A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med (1995) 3.98
Detection of Norwalk virus in stool by polymerase chain reaction. J Clin Microbiol (1992) 3.82
A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology (1989) 3.66
A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A (2000) 3.66
Gastric dysplasia: the Padova international classification. Am J Surg Pathol (2000) 3.66
Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol (1996) 3.57
The course of patients after variceal hemorrhage. Gastroenterology (1981) 3.33
Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure. J Bacteriol (1996) 3.32
Variants of the 3' region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J Clin Microbiol (1998) 3.31
Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Am J Gastroenterol (1996) 3.20
N-acetylneuraminyllactose-binding fibrillar hemagglutinin of Campylobacter pylori: a putative colonization factor antigen. Infect Immun (1988) 3.16
Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology (1994) 3.15
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology (1997) 3.10
Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet (1991) 3.09
Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol (1993) 2.96
Ultrastructural localization of rotavirus antigens using colloidal gold. Virus Res (1984) 2.95
Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology (1992) 2.83
Identification, synthesis, and modifications of simian rotavirus SA11 polypeptides in infected cells. J Virol (1982) 2.67
A plaque assay for the simian rotavirus SAII. J Gen Virol (1979) 2.65
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother (1997) 2.63
Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology (1982) 2.60
Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology (1999) 2.54
Rotavirus stability and inactivation. J Gen Virol (1979) 2.48
Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother (1997) 2.47
Helicobacter pylori infection: genetic and environmental influences. A study of twins. Ann Intern Med (1994) 2.47
Relationship between the cagA 3' repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Gastroenterology (1999) 2.44
Patients, payers, and paradigm shifts: what to do about Helicobacter pylori. Am J Gastroenterol (1996) 2.43
Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Helicobacter (1998) 2.39
Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis (1998) 2.38
Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol (1997) 2.37
Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc (1994) 2.36
Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med (1984) 2.29
Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis (2002) 2.24
An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy (2006) 2.22
Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol (1994) 2.16
Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut (1994) 2.14
Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut (1990) 2.13
Pancreatic-biliary ascariasis: experience of 300 cases. Am J Gastroenterol (1997) 2.10
Mycobacteria and inflammatory bowel disease. Results of culture. Gastroenterology (1987) 2.07
Nucleic acid hybridization studies of mycobactin-dependent mycobacteria. J Clin Microbiol (1988) 2.06
Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol (1987) 2.05
Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology (1980) 2.04
Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther (2006) 2.00
Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol (1993) 2.00
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet (1999) 1.98
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc (2000) 1.97
Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol Infect (2000) 1.97
Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun (1995) 1.97
Helicobacter pylori in the drinking water in Peru. Gastroenterology (1996) 1.95
Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther (2002) 1.94
Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction. J Clin Microbiol (1993) 1.94
Detection of Mycobacterium avium subspecies paratuberculosis in Crohn's diseased tissues by in situ hybridization. Am J Gastroenterol (2001) 1.93
Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virchows Arch (1998) 1.91
Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test. Am J Gastroenterol (1996) 1.89
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med (1999) 1.88
Biochemical mapping of the simian rotavirus SA11 genome. J Virol (1983) 1.88
Letter: the ethics of using inferior regimens in H. pylori randomised trials. Aliment Pharmacol Ther (2012) 1.87
Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol (2005) 1.85
Cloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori. J Bacteriol (1993) 1.85
Factors influencing the epidemiology of Helicobacter pylori infection in children. Pediatrics (1991) 1.82
Proteolytic enhancement of rotavirus infectivity: biology mechanism. Virology (1980) 1.81
Ultrastructural study of rotavirus replication in cultured cells. J Gen Virol (1980) 1.81
Campylobacter pyloridis gastritis: the past, the present, and speculations about the future. Am J Gastroenterol (1987) 1.80
The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol (1990) 1.79
Simian rotavirus SA11 replication in cell cultures. J Virol (1979) 1.79
Prospective randomized comparison of polyvinyl bougies and through-the-scope balloons for dilation of peptic strictures of the esophagus. Gastrointest Endosc (1995) 1.78
Unsaturated fatty acids and viability of Helicobacter (Campylobacter) pylori. J Clin Microbiol (1990) 1.78
Aspirin and the stomach. Ann Intern Med (1986) 1.77
Detection of antigenically distinct rotaviruses from infants. Infect Immun (1983) 1.77
Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol (1997) 1.76
Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol (1999) 1.76
Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 1.75
The molecular epidemiology of rotavirus gastroenteritis. Prog Med Virol (1984) 1.74
Adherence and internalization of Helicobacter pylori by HEp-2 cells. Gastroenterology (1992) 1.74
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology (1989) 1.74
Relation between clinical presentation, Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut (1999) 1.72
Urease-associated heat shock protein of Helicobacter pylori. Infect Immun (1992) 1.71
Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis (1991) 1.69
Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer (1994) 1.68
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother (2001) 1.68
Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med (1991) 1.68
Toothpick perforation of the intestines. Ann Surg (1977) 1.67